News

Company   ImmuPharma PLC
TIDM         IMM
Headline    Directors' Dealings
Released    12:51 18-Dec-07
Number     1788K

FOR IMMEDIATE RELEASE

London, 18 December 2007

Directors’ Dealing
Powe Capital increases stake in ImmuPharma to over 5%

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), announces today that Powe Capital, through its funds Modulus Europe and Tensor Europe, has increased its stake in ImmuPharma from 3.12% to 5.59% through a purchase, on 14 December 2007, of 1,800,000 existing ordinary shares of 10 pence each in the Company from the Trusts of two of ImmuPharma's founders and Directors, Richard Warr and Dimitri Dimitriou.

The subsequent interests are as follows:

	Shares Purchased	Price per share	Subsequent beneficial holding	Subsequent percent interest
Modulus Europe	1,540,000	£0.73	3,808,127	5.23%
Tensor Europe	260,000	£0.73	260,000	0.36%

	Shares Placed	Price per share	Subsequent beneficial holding	Subsequent percent interest
Richard Warr⁽¹⁾	900,000	£0.73	11,878,968	16.32%
Dimitri Dimitriou⁽²⁾	900,000	£0.73	11,878,969	16.32%

(1) Ordinary shares of £0.10 held by Louvre Trustees where the Warr family has a beneficial interest.
(2) Ordinary shares of £0.10 held by Louvre Trustees where the Dimitriou family has a beneficial interest.

Richard Warr, ImmuPharma's Chairman said: "Powe Capital has been a longstanding supporter and shareholder of ImmuPharma. We are delighted by the confidence they have shown in the Company by increasing their stake to over 5%."

For further information please contact:

ImmuPharma PLC

Richard Warr, Chairman +44 20 7152 4080
Dimitri Dimitriou, Chief Executive Officer +44 20 7152 4080

Buchanan Communications + 44 20 7466 5000

Lisa Baderoon
Rebecca Skye-Dietrich

Panmure Gordon & Co +44 151 243 0963

Andrew Burnett